+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Gastrointestinal Drugs Market - Global Forecast 2026-2032- Product Image
Gastrointestinal Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Gastrointestinal Drugs Market - Global Forecast 2026-2032

  • Report

  • 181 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5789600
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Gastrointestinal Drugs Market is projected to reach USD 65.45 Billion in 2026. It is expected to continue growing at a CAGR of 5.45%, reaching USD 90.26 Billion by 2032.

Gastrointestinal drugs remain a core growth area in specialty and primary care because digestive diseases affect large patient populations across gastroesophageal reflux disease, peptic ulcer disease, irritable bowel syndrome, inflammatory bowel disease, constipation, diarrhea, nausea and vomiting, liver-linked complications, and procedure-related bowel preparation. Demand is reinforced by aging demographics, higher diagnosis rates, microbiome science, and the shift from symptom suppression toward disease modification and long-term disease control.

The market spans mature small-molecule categories such as proton pump inhibitors, H2 receptor antagonists, laxatives, antidiarrheals, antispasmodics, antiemetics, and bile acid therapies, alongside biologics, biosimilars, targeted immunomodulators, and microbiota-based therapeutics. Competitive advantage increasingly depends on differentiated clinical outcomes, payer-relevant evidence, tolerability, convenient administration, adherence support, and the ability to serve both high-volume gastrointestinal conditions and severe chronic diseases requiring long-term therapy.

Transformative Shifts in the Gastrointestinal Drugs Landscape

The gastrointestinal drugs landscape is being reshaped by precision medicine, biologic competition, and growing use of real-world evidence. In inflammatory bowel disease, therapeutic selection is moving beyond broad anti-inflammatory control toward mechanisms such as integrin inhibition, interleukin pathway modulation, Janus kinase inhibition, sphingosine-1-phosphate receptor modulation, and biosimilar adoption. In functional gastrointestinal disorders, patient-reported outcomes, symptom frequency, abdominal pain reduction, bowel habit normalization, and quality-of-life measures are becoming central to product differentiation.

Another major shift is the expansion of microbiome-based approaches and combination care models that link diagnostics, nutrition, digital monitoring, endoscopy, and pharmacotherapy. At the same time, generic erosion in legacy acid-suppression, antiemetic, and motility categories is increasing pricing pressure, pushing manufacturers to invest in specialty indications, novel delivery systems, fixed-dose strategies, and evidence packages that demonstrate reduced hospital utilization, fewer disease flares, improved remission durability, and better long-term adherence.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is compounding change across gastrointestinal drug discovery, clinical development, pharmacovigilance, and commercialization. AI-enabled target identification supports analysis of genomics, proteomics, metabolomics, microbiome datasets, imaging outputs, and inflammatory pathways, helping researchers prioritize mechanisms with stronger biological plausibility. In clinical trials, machine learning can improve site selection, patient stratification, endpoint prediction, protocol feasibility, and recruitment for diseases with heterogeneous presentation such as Crohn’s disease, ulcerative colitis, irritable bowel syndrome, gastroparesis, and functional dyspepsia.

The cumulative impact is also visible in post-market surveillance and medical engagement. AI can detect adverse-event signals across structured and unstructured data, support claims-based outcomes research, identify adherence barriers, and personalize educational content for physicians and patients. However, leaders must manage data quality, algorithm transparency, bias control, privacy compliance, cybersecurity, and regulatory expectations to ensure AI improves evidence generation without weakening scientific rigor or patient trust.

Key Regional Insights

North America remains a leading region for gastrointestinal drug innovation due to advanced specialty care infrastructure, high use of biologics, substantial clinical trial activity, and established FDA pathways for novel drugs, biosimilars, and microbiota-based therapies. Europe benefits from broad public reimbursement systems, coordinated regulatory review through the EMA, and strong gastroenterology networks, while access decisions place heavy emphasis on health technology assessment, cost-effectiveness, biosimilar competition, and real-world outcomes evidence.

Asia-Pacific is gaining strategic importance as China, India, Japan, South Korea, and Australia expand diagnosis, clinical research participation, endoscopic capacity, and access to specialty gastrointestinal therapies. Latin America shows rising demand in Brazil, Mexico, and regional private healthcare systems, although affordability, public formulary inclusion, and reimbursement variability influence uptake. The Middle East is investing in advanced hospitals and specialty care, especially across GCC markets, while Africa presents long-term access opportunities shaped by essential medicines availability, infectious gastrointestinal disease burden, local distribution capacity, and expanding urban healthcare infrastructure.

Key Group Insights

ASEAN is becoming more relevant for gastrointestinal drug access as Indonesia, Thailand, Vietnam, Malaysia, Singapore, and the Philippines expand healthcare coverage, private hospital networks, diagnostics, and specialist capacity. The GCC shows strong demand for premium therapies supported by national health investment, high specialty-care spending, digital health modernization, and a policy focus on local pharmaceutical capability. The European Union remains critical for evidence-driven access, where centralized regulation and national reimbursement decisions create both scale and scrutiny for gastrointestinal drugs, particularly biologics, biosimilars, and advanced therapies.

BRICS markets combine large patient populations with expanding domestic pharmaceutical capacity, making China, India, Brazil, Russia, and South Africa important for volume access, clinical development, and manufacturing resilience. G7 countries continue to set standards for innovation, pricing debate, pharmacovigilance, patient safety, and evidence-based prescribing. NATO-aligned markets are significant because supply security, regulatory alignment, medicine stockpiling, and resilient access to essential and specialty medicines have become more prominent healthcare priorities following recent global supply disruptions.

Key Country Insights

The United States leads in specialty gastrointestinal drug spending, clinical trials, guideline adoption, and rapid uptake of innovative therapies, while Canada emphasizes health technology assessment, reimbursement review, and equitable provincial access. Mexico and Brazil are important Latin American markets where expanding middle-class healthcare demand and private-sector access coexist with formulary, distribution, and affordability constraints. In Europe, the United Kingdom, Germany, France, Italy, and Spain represent major access environments shaped by national health systems, HTA requirements, reference pricing, prescribing controls, and increasing biosimilar use, while Russia maintains demand for both local production and imported specialty medicines.

China and India are central to future gastrointestinal drug access because of scale, improving diagnosis, domestic manufacturing, biosimilar development, and greater participation in global clinical development. Japan remains a sophisticated market with strong clinical standards, aging-related gastrointestinal demand, and disciplined reimbursement review, while South Korea is recognized for advanced healthcare infrastructure, biosimilars, digital hospital systems, and clinical research capability. Australia adds value through transparent reimbursement processes, specialist networks, pharmacovigilance standards, and high expectations for evidence-based prescribing.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated mechanisms, measurable outcomes, and lifecycle strategies that withstand generic and biosimilar pressure. Successful portfolios will combine high-volume gastrointestinal therapies with specialty assets in inflammatory bowel disease, functional bowel disorders, microbiome-related disease, liver-associated complications, acid-related disorders, and motility disorders. Companies should design trials with payer-relevant endpoints, including clinical remission, endoscopic improvement, steroid-free response, reduced hospitalization, lower flare frequency, treatment persistence, and patient-reported symptom improvement.

Commercial teams should build region-specific access strategies, invest in real-world evidence, and strengthen physician education around diagnosis, treatment sequencing, switching, adherence, and safety monitoring. Manufacturing leaders should secure active pharmaceutical ingredient supply, expand quality oversight, improve cold-chain readiness for biologics, and evaluate local production partnerships in fast-growing markets. AI should be deployed through governed frameworks that align data science, medical affairs, regulatory, legal, compliance, cybersecurity, and pharmacovigilance functions.

Research Methodology

This executive summary is based on structured secondary research, regulatory review, therapeutic-area analysis, and cross-regional market assessment. Inputs include publicly available information from health authorities, clinical trial registries, peer-reviewed medical literature, prescribing guidance, drug labels, treatment guidelines, reimbursement frameworks, and recognized public health sources such as the FDA, EMA, WHO, CDC, NIH, and national health agencies.

The methodology emphasizes verified, data-backed interpretation rather than speculative projections. Market dynamics were assessed across disease burden, product class maturity, clinical innovation, regulatory pathways, reimbursement pressure, competitive intensity, biosimilar adoption, regional access conditions, supply-chain resilience, and technology adoption. Insights were synthesized to support executive decision-making for pharmaceutical manufacturers, healthcare investors, distributors, payers, providers, and policy stakeholders.

Conclusion

The gastrointestinal drugs market is evolving from a mature primary-care category into a multi-layered therapeutic landscape defined by specialty innovation, biologics, biosimilars, microbiome science, precision medicine, and AI-enabled evidence generation. High-prevalence conditions sustain baseline demand, while chronic immune-mediated, functional, acid-related, and motility disorders create opportunities for differentiated therapies and long-term patient management.

Future leadership will depend on clinical relevance, access strategy, manufacturing resilience, regulatory readiness, and credible real-world outcomes. Companies that align scientific innovation with affordability, regional execution, patient-centered evidence, and digital intelligence will be best positioned to capture sustainable growth in gastrointestinal therapeutics.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Gastrointestinal Drugs Market, by Drug Class
7.1. Introduction
7.2. Antacids
7.2.1. Aluminum Hydroxide
7.2.2. Calcium Carbonate
7.2.3. Magnesium Hydroxide
7.2.4. Sodium Bicarbonate
7.3. Antidiarrheals
7.3.1. Bismuth Subsalicylate
7.3.2. Loperamide
7.4. Antispasmodics
7.4.1. Dicyclomine
7.4.2. Hyoscyamine
7.5. Laxatives
7.6. Proton Pump Inhibitors
7.6.1. Omeprazole
7.6.2. Esomeprazole
7.6.3. Lansoprazole
7.6.4. Rabeprazole
7.7. Prokinetics
7.7.1. Dopamine Antagonists
7.7.2. Serotonin 5-HT4 Agonists
7.7.3. Macrolide Prokinetics
7.8. Antiemetics
7.8.1. Ondansetron
7.8.2. Prochlorperazine
8. Gastrointestinal Drugs Market, by Route Of Administration
8.1. Introduction
8.2. Injectable
8.2.1. Intramuscular
8.2.2. Intravenous
8.3. Oral
8.3.1. Capsules
8.3.1.1. Hard Shell
8.3.1.2. Soft Gel
8.3.2. Powders
8.3.3. Tablets
8.4. Rectal
9. Gastrointestinal Drugs Market, by Molecule Type
9.1. Introduction
9.2. Small Molecule
9.3. Biologic
9.4. Biosimilar
9.5. Peptide
9.6. Enzyme Replacement
9.7. Recombinant Protein
9.8. Live Biotherapeutic
10. Gastrointestinal Drugs Market, by Formulation Type
10.1. Introduction
10.2. Immediate Release
10.3. Extended Release
10.4. Enteric Coated
10.5. Fixed Dose Combination
10.6. Liquid Formulation
11. Gastrointestinal Drugs Market, by Indication
11.1. Introduction
11.2. Constipation
11.3. Gastroesophageal Reflux Disease
11.4. Diarrhea
11.5. Irritable Bowel Syndrome
11.6. Peptic Ulcer Disease
11.7. Inflammatory Bowel Disease
11.7.1. Crohn's Disease
11.7.2. Ulcerative Colitis
11.8. Gastroparesis
12. Gastrointestinal Drugs Market, by End User
12.1. Introduction
12.2. Clinics
12.2.1. Gastroenterology Clinics
12.2.2. General Practice Clinics
12.3. Home Healthcare
12.4. Hospitals
13. Gastrointestinal Drugs Market, by Distribution Channel
13.1. Introduction
13.2. Offline
13.2.1. Hospital Pharmacies
13.2.2. Retail Pharmacies
13.2.3. Specialty Pharmacies
13.3. Online Pharmacies
14. Gastrointestinal Drugs Market, by Region
14.1. Asia-Pacific
14.2. Europe
14.3. North America
14.4. Latin America
14.5. Africa
14.6. Middle East
15. Gastrointestinal Drugs Market, by Group
15.1. NATO
15.2. G7
15.3. European Union
15.4. BRICS
15.5. ASEAN
15.6. GCC
16. Gastrointestinal Drugs Market, by Country
16.1. United States
16.2. China
16.3. Germany
16.4. Japan
16.5. India
16.6. United Kingdom
16.7. France
16.8. Canada
16.9. Australia
16.10. Italy
16.11. Brazil
16.12. Mexico
16.13. South Korea
16.14. Russia
16.15. Spain
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. FPNV Positioning Matrix, 2025
17.3. Market Concentration Analysis, 2025
17.3.1. Concentration Ratio (CR)
17.3.2. Herfindahl Hirschman Index (HHI)
17.4. Recent Developments & Impact Analysis, 2025
17.5. Product Portfolio Analysis, 2025
17.6. Benchmarking Analysis, 2025
18. Company Profiles
18.1. AbbVie Inc.
18.2. Amgen Inc.
18.3. AstraZeneca PLC
18.4. Bausch Health Companies Inc.
18.5. Bayer AG
18.6. Boehringer Ingelheim International GmbH
18.7. Bristol-Myers Squibb
18.8. Cipla Limited
18.9. Cosmo Pharmaceuticals N.V.
18.10. Dr. Reddy’s Laboratories Ltd.
18.11. Eli Lilly and Company
18.12. F. Hoffmann-La Roche Ltd
18.13. Ferring International Center S.A.
18.14. GlaxoSmithKline plc
18.15. Ironwood Pharmaceuticals, Inc.
18.16. Johnson & Johnson Services, Inc.
18.17. Merck & Co., Inc.
18.18. Novartis AG
18.19. Otsuka Pharmaceutical Co., Ltd.
18.20. Pfizer Inc.
18.21. Reckitt Benckiser Group plc
18.22. Sanofi S.A.
18.23. Takeda Pharmaceutical Company Limited
18.24. Teva Pharmaceutical Industries Ltd.
18.25. Viatris Inc.
List of Figures
FIGURE 1. GLOBAL GASTROINTESTINAL DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL GASTROINTESTINAL DRUGS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL GASTROINTESTINAL DRUGS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL GASTROINTESTINAL DRUGS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY FORMULATION TYPE, 2025 VS 2032 (%)
FIGURE 13. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY FORMULATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 19. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 23. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 25. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL GASTROINTESTINAL DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 27. GLOBAL GASTROINTESTINAL DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL GASTROINTESTINAL DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL ANTACIDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL ANTACIDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL ANTACIDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL ALUMINUM HYDROXIDE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL ALUMINUM HYDROXIDE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL ALUMINUM HYDROXIDE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL CALCIUM CARBONATE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL CALCIUM CARBONATE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL CALCIUM CARBONATE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL MAGNESIUM HYDROXIDE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL MAGNESIUM HYDROXIDE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL MAGNESIUM HYDROXIDE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL SODIUM BICARBONATE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL SODIUM BICARBONATE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL SODIUM BICARBONATE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL ANTIDIARRHEALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL ANTIDIARRHEALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL ANTIDIARRHEALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL BISMUTH SUBSALICYLATE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL BISMUTH SUBSALICYLATE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL BISMUTH SUBSALICYLATE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL LOPERAMIDE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL LOPERAMIDE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL LOPERAMIDE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL ANTISPASMODICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL ANTISPASMODICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL ANTISPASMODICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL DICYCLOMINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL DICYCLOMINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL DICYCLOMINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL HYOSCYAMINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL HYOSCYAMINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL HYOSCYAMINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL LAXATIVES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL LAXATIVES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL LAXATIVES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL PROTON PUMP INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL PROTON PUMP INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL PROTON PUMP INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL OMEPRAZOLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL OMEPRAZOLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL OMEPRAZOLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL LANSOPRAZOLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL LANSOPRAZOLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL LANSOPRAZOLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL RABEPRAZOLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL RABEPRAZOLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL RABEPRAZOLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL PROKINETICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL PROKINETICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL PROKINETICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL DOPAMINE ANTAGONISTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL DOPAMINE ANTAGONISTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL DOPAMINE ANTAGONISTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL SEROTONIN 5-HT4 AGONISTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL SEROTONIN 5-HT4 AGONISTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL SEROTONIN 5-HT4 AGONISTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL MACROLIDE PROKINETICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL MACROLIDE PROKINETICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL MACROLIDE PROKINETICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL ANTIEMETICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL ANTIEMETICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL ANTIEMETICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL ONDANSETRON MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL ONDANSETRON MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL ONDANSETRON MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL PROCHLORPERAZINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL PROCHLORPERAZINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL PROCHLORPERAZINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL HARD SHELL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL HARD SHELL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL HARD SHELL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL SOFT GEL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL SOFT GEL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL SOFT GEL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL POWDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL POWDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL POWDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL TABLETS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL RECTAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL RECTAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL RECTAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL SMALL MOLECULE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL SMALL MOLECULE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL SMALL MOLECULE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL BIOLOGIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL BIOLOGIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL BIOLOGIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL BIOSIMILAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL BIOSIMILAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL BIOSIMILAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL PEPTIDE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL PEPTIDE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL PEPTIDE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL ENZYME REPLACEMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL ENZYME REPLACEMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL ENZYME REPLACEMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL RECOMBINANT PROTEIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL RECOMBINANT PROTEIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL RECOMBINANT PROTEIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL LIVE BIOTHERAPEUTIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL LIVE BIOTHERAPEUTIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL LIVE BIOTHERAPEUTIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL IMMEDIATE RELEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL IMMEDIATE RELEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 132. GLOBAL IMMEDIATE RELEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 133. GLOBAL EXTENDED RELEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 134. GLOBAL EXTENDED RELEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 135. GLOBAL EXTENDED RELEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 136. GLOBAL ENTERIC COATED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 137. GLOBAL ENTERIC COATED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 138. GLOBAL ENTERIC COATED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 139. GLOBAL FIXED DOSE COMBINATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 140. GLOBAL FIXED DOSE COMBINATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 141. GLOBAL FIXED DOSE COMBINATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 142. GLOBAL LIQUID FORMULATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 143. GLOBAL LIQUID FORMULATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 144. GLOBAL LIQUID FORMULATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 145. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 146. GLOBAL CONSTIPATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 147. GLOBAL CONSTIPATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 148. GLOBAL CONSTIPATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 149. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 150. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 151. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 152. GLOBAL DIARRHEA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 153. GLOBAL DIARRHEA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 154. GLOBAL DIARRHEA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 155. GLOBAL IRRITABLE BOWEL SYNDROME MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 156. GLOBAL IRRITABLE BOWEL SYNDROME MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 157. GLOBAL IRRITABLE BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 158. GLOBAL PEPTIC ULCER DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 159. GLOBAL PEPTIC ULCER DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 160. GLOBAL PEPTIC ULCER DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 161. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 162. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 163. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 164. GLOBAL CROHN'S DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 165. GLOBAL CROHN'S DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 166. GLOBAL CROHN'S DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 167. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 168. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 169. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 170. GLOBAL GASTROPARESIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 171. GLOBAL GASTROPARESIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 172. GLOBAL GASTROPARESIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 173. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 174. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 175. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 176. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 177. GLOBAL GASTROENTEROLOGY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 178. GLOBAL GASTROENTEROLOGY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 179. GLOBAL GASTROENTEROLOGY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 180. GLOBAL GENERAL PRACTICE CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 181. GLOBAL GENERAL PRACTICE CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 182. GLOBAL GENERAL PRACTICE CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 183. GLOBAL HOME HEALTHCARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 184. GLOBAL HOME HEALTHCARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 185. GLOBAL HOME HEALTHCARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 186. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 187. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 188. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 189. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 190. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 191. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 192. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 193. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 194. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 195. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 196. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 197. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 198. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 199. GLOBAL SPECIALTY PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 200. GLOBAL SPECIALTY PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 201. GLOBAL SPECIALTY PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 202. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 203. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 204. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 205. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 206. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 207. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 208. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTACIDS, 2017-2032 (USD MILLION)
TABLE 209. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIDIARRHEALS, 2017-2032 (USD MILLION)
TABLE 210. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTISPASMODICS, 2017-2032 (USD MILLION)
TABLE 211. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2017-2032 (USD MILLION)
TABLE 212. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY PROKINETICS, 2017-2032 (USD MILLION)
TABLE 213. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIEMETICS, 2017-2032 (USD MILLION)
TABLE 214. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 215. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 216. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 217. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY CAPSULES, 2017-2032 (USD MILLION)
TABLE 218. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 219. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 220. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 221. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2017-2032 (USD MILLION)
TABLE 222. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 223. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY CLINICS, 2017-2032 (USD MILLION)
TABLE 224. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 225. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 226. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 227. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 228. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTACIDS, 2017-2032 (USD MILLION)
TABLE 229. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIDIARRHEALS, 2017-2032 (USD MILLION)
TABLE 230. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTISPASMODICS, 2017-2032 (USD MILLION)
TABLE 231. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2017-2032 (USD MILLION)
TABLE 232. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY PROKINETICS, 2017-2032 (USD MILLION)
TABLE 233. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIEMETICS, 2017-2032 (USD MILLION)
TABLE 234. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 235. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 236. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 237. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY CAPSULES, 2017-2032 (USD MILLION)
TABLE 238. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 239. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 240. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 241. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2017-2032 (USD MILLION)
TABLE 242. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 243. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY CLINICS, 2017-2032 (USD MILLION)
TABLE 244. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 245. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 246. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 247. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 248. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTACIDS, 2017-2032 (USD MILLION)
TABLE 249. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIDIARRHEALS, 2017-2032 (USD MILLION)
TABLE 250. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTISPASMODICS, 2017-2032 (USD MILLION)
TABLE 251. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2017-2032 (USD MILLION)
TABLE 252. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY PROKINETICS, 2017-2032 (USD MILLION)
TABLE 253. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIEMETICS, 2017-2032 (USD MILLION)
TABLE 254. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 255. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 256. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 257. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY CAPSULES, 2017-2032 (USD MILLION)
TABLE 258. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 259. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 260. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 261. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2017-2032 (USD MILLION)
TABLE 262. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 263. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY CLINICS, 2017-2032 (USD MILLION)
TABLE 264. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 265. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 266. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 267. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 268. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTACIDS, 2017-2032 (USD MILLION)
TABLE 269. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIDIARRHEALS, 2017-2032 (USD MILLION)
TABLE 270. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTISPASMODICS, 2017-2032 (USD MILLION)
TABLE 271. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2017-2032 (USD MILLION)
TABLE 272. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY PROKINETICS, 2017-2032 (USD MILLION)
TABLE 273. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIEMETICS, 2017-2032 (USD MILLION)
TABLE 274. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 275. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 276. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 277. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY CAPSULES, 2017-2032 (USD MILLION)
TABLE 278. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 279. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 280. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 281. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2017-2032 (USD MILLION)
TABLE 282. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 283. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY CLINICS, 2017-2032 (USD MILLION)
TABLE 284. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 285. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 286. AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 287. AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 288. AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTACIDS, 2017-2032 (USD MILLION)
TABLE 289. AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIDIARRHEALS, 2017-2032 (USD MILLION)
TABLE 290. AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTISPASMODICS, 2017-2032 (USD MILLION)
TABLE 291. AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2017-2032 (USD MILLION)
TABLE 292. AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY PROKINETICS, 2017-2032 (USD MILLION)
TABLE 293. AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIEMETICS, 2017-2032 (USD MILLION)
TABLE 294. AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 295. AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 296. AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 297. AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY CAPSULES, 2017-2032 (USD MILLION)
TABLE 298. AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 299. AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 300. AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 301. AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2017-2032 (USD MILLION)
TABLE 302. AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 303. AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY CLINICS, 2017-2032 (USD MILLION)
TABLE 304. AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 305. AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 306. MIDDLE EAST GASTROINTESTINAL DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 307. MIDDLE EAST GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 308. MIDDLE EAST GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTACIDS, 2017-2032 (USD MILLION)
TABLE 309. MIDDLE EAST GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIDIARRHEALS, 2017-2032 (USD MILLION)
TABLE 310. MIDDLE EAST GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTISPASMODICS, 2017-2032 (USD MILLION)
TABLE 311. MIDDLE EAST GASTROINTESTINAL DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2017-2032 (USD MILLION)
TABLE 312. MIDDLE EAST GASTROINTESTINAL DRUGS MARKET SIZE, BY PROKINETICS, 2017-2032 (USD MILLION)
TABLE 313. MIDDLE EAST GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIEMETICS, 2017-2032 (USD MILLION)
TABLE 314. MIDDLE EAST GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 315. MIDDLE EAST GASTROINTESTINAL DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 316. MIDDLE EAST GASTROINTESTINAL DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 317. MIDDLE EAST GASTROINTESTINAL DRUGS MARKET SIZE, BY CAPSULES, 2017-2032 (USD MILLION)
TABLE 318. MIDDLE EAST GASTROINTESTINAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 319. MIDDLE EAST GASTROINTESTINAL DRUGS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 320. MIDDLE EAST GASTROINTESTINAL DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 321. MIDDLE EAST GASTROINTESTINAL DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2017-2032 (USD MILLION)
TABLE 322. MIDDLE EAST GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 323. MIDDLE EAST GASTROINTESTINAL DRUGS MARKET SIZE, BY CLINICS, 2017-2032 (USD MILLION)
TABLE 324. MIDDLE EAST GASTROINTESTINAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 325. MIDDLE EAST GASTROINTESTINAL DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 326. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 327. NATO GASTROINTESTINAL DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 328. NATO GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 329. NATO GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTACIDS, 2017-2032 (USD MILLION)
TABLE 330. NATO GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIDIARRHEALS, 2017-2032 (USD MILLION)
TABLE 331. NATO GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTISPASMODICS, 2017-2032 (USD MILLION)
TABLE 332. NATO GASTROINTESTINAL DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2017-2032 (USD MILLION)
TABLE 333. NATO GASTROINTESTINAL DRUGS MARKET SIZE, BY PROKINETICS, 2017-2032 (USD MILLION)
TABLE 334. NATO GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIEMETICS, 2017-2032 (USD MILLION)
TABLE 335. NATO GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 336. NATO GASTROINTESTINAL DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 337. NATO GASTROINTESTINAL DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 338. NATO GASTROINTESTINAL DRUGS MARKET SIZE, BY CAPSULES, 2017-2032 (USD MILLION)
TABLE 339. NATO GASTROINTESTINAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 340. NATO GASTROINTESTINAL DRUGS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 341. NATO GASTROINTESTINAL DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 342. NATO GASTROINTESTINAL DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2017-2032 (USD MILLION)
TABLE 343. NATO GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 344. NATO GASTROINTESTINAL DRUGS MARKET SIZE, BY CLINICS, 2017-2032 (USD MILLION)
TABLE 345. NATO GASTROINTESTINAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 346. NATO GASTROINTESTINAL DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 347. G7 GASTROINTESTINAL DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 348. G7 GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 349. G7 GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTACIDS, 2017-2032 (USD MILLION)
TABLE 350. G7 GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIDIARRHEALS, 2017-2032 (USD MILLION)
TABLE 351. G7 GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTISPASMODICS, 2017-2032 (USD MILLION)
TABLE 352. G7 GASTROINTESTINAL DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2017-2032 (USD MILLION)
TABLE 353. G7 GASTROINTESTINAL DRUGS MARKET SIZE, BY PROKINETICS, 2017-2032 (USD MILLION)
TABLE 354. G7 GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIEMETICS, 2017-2032 (USD MILLION)
TABLE 355. G7 GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 356. G7 GASTROINTESTINAL DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 357. G7 GASTROINTESTINAL DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 358. G7 GASTROINTESTINAL DRUGS MARKET SIZE, BY CAPSULES, 2017-2032 (USD MILLION)
TABLE 359. G7 GASTROINTESTINAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 360. G7 GASTROINTESTINAL DRUGS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 361. G7 GASTROINTESTINAL DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 362. G7 GASTROINTESTINAL DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2017-2032 (USD MILLION)
TABLE 363. G7 GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 364. G7 GASTROINTESTINAL DRUGS MARKET SIZE, BY CLINICS, 2017-2032 (USD MILLION)
TABLE 365. G7 GASTROINTESTINAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 366. G7 GASTROINTESTINAL DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 367. EUROPEAN UNION GASTROINTESTINAL DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 368. EUROPEAN UNION GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 369. EUROPEAN UNION GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTACIDS, 2017-2032 (USD MILLION)
TABLE 370. EUROPEAN UNION GASTROI

Companies Mentioned

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb
  • Cipla Limited
  • Cosmo Pharmaceuticals N.V.
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann‑La Roche Ltd
  • Ferring International Center S.A.
  • GlaxoSmithKline plc
  • Ironwood Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Reckitt Benckiser Group plc
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages181
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 65.45 Billion
Forecasted Market Value ( USD ) by 2032 $ 90.26 Billion
Compound Annual Growth Rate5.4%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Gastrointestinal Drugs Market - A Global and Regional Analysis: Focus on Application, Route of Administration, Distribution Channel, Drug Class, and Country-Level Analysis - Analysis and Forecast, 2025-2035 - Product Image

Gastrointestinal Drugs Market - A Global and Regional Analysis: Focus on Application, Route of Administration, Distribution Channel, Drug Class, and Country-Level Analysis - Analysis and Forecast, 2025-2035

  • Report
  • Global
From
Gastrointestinal Therapeutics - Global Strategic Business Report - Product Image

Gastrointestinal Therapeutics - Global Strategic Business Report

  • Report
  • 497 Pages
  • Global
From
Gastrointestinal Diseases Therapeutics Market - Global Forecast 2026-2032 - Product Image

Gastrointestinal Diseases Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Gastroparesis Drugs Market - Global Forecast 2026-2032 - Product Image

Gastroparesis Drugs Market - Global Forecast 2026-2032

  • Report
  • 199 Pages
  • Global
From
Dyspepsia Drugs - Global Strategic Business Report - Product Image

Dyspepsia Drugs - Global Strategic Business Report

  • Report
  • 566 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.